SG11201708323SA - Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders - Google Patents

Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

Info

Publication number: SG11201708323SA
Authority: SG; Singapore
Prior art keywords: antibodies; antigen binding; binding agents; metabolic disorders; treat metabolic
Prior art date: 2015-04-30

Application number

SG11201708323SA

Inventor

Gökhan S Hotamisligil

Mehmet F Burak

Feyza Engin

Scott B Widenmaier

Elisabeth Helen Roberts

Adrian Richard Moore

Carl Brendan Doyle

Ralph Adams

Karine Jeannine Madeleine Hervé

Shauna Mhairi Wales

Kerry Louise Tyson

Original Assignee

Harvard College

Ucb Biopharma Sprl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-30

Filing date

2016-04-29

Publication date

2017-11-29

2016-04-29 Application filed by Harvard College, Ucb Biopharma Sprl filed Critical Harvard College

2017-11-29 Publication of SG11201708323SA publication Critical patent/SG11201708323SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)

SG11201708323SA 2015-04-30 2016-04-29 Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders SG11201708323SA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562155217P	2015-04-30	2015-04-30
US201562232148P	2015-09-24	2015-09-24
US201562268257P	2015-12-16	2015-12-16
PCT/US2016/030303 WO2016176656A2 (en)	2015-04-30	2016-04-29	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

Publications (1)

Publication Number	Publication Date
SG11201708323SA true SG11201708323SA (en)	2017-11-29

Family

ID=56134548

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201708323SA SG11201708323SA (en)	2015-04-30	2016-04-29	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

Country Status (17)

Country	Link
US (3)	US10160798B2 (en)
EP (1)	EP3288584A2 (en)
JP (1)	JP2018515082A (en)
KR (1)	KR20170138570A (en)
CN (1)	CN107667116A (en)
AU (1)	AU2016254215A1 (en)
BR (1)	BR112017023158A2 (en)
CA (1)	CA2982427A1 (en)
CL (1)	CL2017002737A1 (en)
CO (1)	CO2017012385A2 (en)
EA (1)	EA201792388A1 (en)
IL (1)	IL255314A0 (en)
MX (1)	MX2017013807A (en)
SG (1)	SG11201708323SA (en)
TW (1)	TW201702271A (en)
UY (1)	UY36663A (en)
WO (1)	WO2016176656A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG11201708323SA (en) *	2015-04-30	2017-11-29	Harvard College	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
CA3066733A1 (en) *	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
US20200375965A1 (en) *	2018-02-19	2020-12-03	The Brigham And Women's Hospital, Inc.	Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM)
WO2021226600A2 (en) *	2020-05-08	2021-11-11	President And Fellows Of Harvard College	Treatment of metabolic disorders through the targeting of a novel circulating hormone complex
WO2023164727A1 (en) *	2022-02-28	2023-08-31	University Of Iowa Research Foundation	A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
CN118047862A (en) *	2022-11-17	2024-05-17	港大科桥有限公司	A-FABP neutralizing monoclonal antibody, preparation method and application thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3674836A (en)	1968-05-21	1972-07-04	Parke Davis & Co	2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en)	1973-06-11	1977-05-31	Merck & Co., Inc.	Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (en)	1974-06-07	1981-03-18
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
MX7065E (en)	1980-06-06	1987-04-10	Sankyo Co	A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4450171A (en)	1980-08-05	1984-05-22	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4448784A (en)	1982-04-12	1984-05-15	Hoechst-Roussel Pharmaceuticals, Inc.	1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4499289A (en)	1982-12-03	1985-02-12	G. D. Searle & Co.	Octahydronapthalenes
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en)	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en)	1984-07-24	1987-08-11	Sandoz Pharmaceuticals Corp.	Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4647576A (en)	1984-09-24	1987-03-03	Warner-Lambert Company	Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
AU599580B2 (en)	1984-12-04	1990-07-26	Sandoz Ag	Indene analogs of mevalonolactone
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4668794A (en)	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
DK336987D0 (en)	1987-07-01	1987-07-01	Novo Industri As	immobilization
WO1987002662A2 (en)	1985-10-25	1987-05-07	Sandoz Ag	Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
FR2596393B1 (en)	1986-04-01	1988-06-03	Sanofi Sa	HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
SE503210C2 (en)	1987-05-22	1996-04-22	Squibb & Sons Inc	Phosphorus-containing HMG-CoA-Reductase Inhibitor, New Intermediates and Methods
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4759923A (en)	1987-06-25	1988-07-26	Hercules Incorporated	Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US4871721A (en)	1988-01-11	1989-10-03	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors
US4924024A (en)	1988-01-11	1990-05-08	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (en)	1988-01-20	1995-07-05	Bayer Ag	Analogous process for the preparation of substituted pyridines, as well as intermediates for use in the preparation
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
FI94339C (en)	1989-07-21	1995-08-25	Warner Lambert Co	Process for the preparation of pharmaceutically acceptable [R- (R , R )] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1991017764A1 (en)	1990-05-16	1991-11-28	Dana Farber Cancer Institute	Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
DE69233254T2 (en)	1991-06-14	2004-09-16	Genentech, Inc., South San Francisco	Humanized Heregulin antibody
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5470845A (en)	1992-10-28	1995-11-28	Bristol-Myers Squibb Company	Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
WO1994016693A1 (en)	1993-01-19	1994-08-04	Warner-Lambert Company	Stable oral ci-981 formulation and process of preparing same
FR2716640B1 (en)	1994-02-28	1996-05-03	Procedes Machines Speciales	Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5385929A (en)	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
AU6966696A (en)	1995-10-05	1997-04-28	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
US5889167A (en)	1996-05-22	1999-03-30	Merck & Co., Inc.	Synthetic glucagon binding proteins
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
CA2344300A1 (en)	1998-09-17	2000-03-23	Jeffrey A. Robl	Method for treating atherosclerosis employing an ap2 inhibitor and combination
JP2002536459A (en) *	1999-02-12	2002-10-29	プレジデントアンドフェローズオブハーヴァードカレッジ	Inhibition of the formation of atherosclerotic lesions
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US7390824B1 (en)	1999-09-07	2008-06-24	Bristol-Myers Squibb Company	Method for treating diabetes employing an aP2 inhibitor and combination
AU2001268855A1 (en)	2000-05-26	2001-12-03	National Research Council Of Canada	Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1409536A2 (en)	2001-02-12	2004-04-21	Curagen Corporation	Human proteins and nucleic acids encoding same
EP1414461A4 (en)	2001-07-13	2005-10-26	Bristol Myers Squibb Co	Pyrazinone inhibitors of fatty acid binding protein and method
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1443919A4 (en) *	2001-11-16	2006-03-22	Bristol Myers Squibb Co	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
AU2003217912A1 (en) *	2002-03-01	2003-09-16	Xencor	Antibody optimization
ATE528648T1 (en)	2002-12-03	2011-10-15	Ucb Pharma Sa	METHOD FOR DETECTING ANTIBODY PRODUCING CELLS
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
DK1644412T4 (en)	2003-07-01	2018-11-12	Ucb Biopharma Sprl	MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
PL1904082T3 (en)	2005-07-21	2010-12-31	Biovendor Laboratory Medicine Inc	METHOD FOR DETERMINING THE CONCENTRATION OF THE ADIPOCYTIC FORM OF THE FATTY ACID BINDING PROTEIN (A-FABP, FABP4, aP2)
WO2007024715A2 (en)	2005-08-19	2007-03-01	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
WO2008144753A2 (en) *	2007-05-21	2008-11-27	Alder Biopharmaceuticals, Inc.	Antibodies to tnf alpha and use thereof
US7906117B2 (en) *	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
JP5592792B2 (en)	2007-09-26	2014-09-17	ユセベファルマソシエテアノニム	Bispecific antibody fusions
KR101161378B1 (en)	2008-09-09	2012-07-02	엘지전자 주식회사	Thin-film type solar cell having white reflective media layer and fabricating method thereof
CA2737241C (en)	2008-09-26	2017-08-29	Ucb Pharma S.A.	Multivalent antibody fusion proteins
CA2744228C (en)	2008-11-20	2018-06-19	Angioblast Systems, Inc.	Method for treating or preventing a pancreatic dysfunction
PT2403605E (en)	2009-03-05	2015-08-05	Harvard College	Compositions comprising an ap2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
TW201427658A (en)	2012-12-10	2014-07-16	Merck Sharp & Dohme	Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
US9062104B2 (en) *	2013-03-14	2015-06-23	Alderbio Holdings Llc	Therapeutic use of antibodies to HGF
CN103665139A (en) *	2013-11-29	2014-03-26	中国药科大学	Adipocyte fatty-acid binding protein and preparation and application of monoclonal antibody of adipocyte fatty-acid binding protein
WO2016044337A1 (en)	2014-09-16	2016-03-24	Regeneron Pharmaceuticals, Inc.	Anti-glucagon antibodies and uses thereof
SG11201708323SA (en) *	2015-04-30	2017-11-29	Harvard College	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

2016
- 2016-04-29 SG SG11201708323SA patent/SG11201708323SA/en unknown
- 2016-04-29 MX MX2017013807A patent/MX2017013807A/en unknown
- 2016-04-29 US US15/143,162 patent/US10160798B2/en active Active
- 2016-04-29 EP EP16730052.4A patent/EP3288584A2/en not_active Withdrawn
- 2016-04-29 KR KR1020177034758A patent/KR20170138570A/en unknown
- 2016-04-29 JP JP2017556973A patent/JP2018515082A/en not_active Abandoned
- 2016-04-29 CN CN201680024952.4A patent/CN107667116A/en active Pending
- 2016-04-29 BR BR112017023158A patent/BR112017023158A2/en not_active IP Right Cessation
- 2016-04-29 WO PCT/US2016/030303 patent/WO2016176656A2/en active Application Filing
- 2016-04-29 EA EA201792388A patent/EA201792388A1/en unknown
- 2016-04-29 CA CA2982427A patent/CA2982427A1/en not_active Abandoned
- 2016-04-29 AU AU2016254215A patent/AU2016254215A1/en not_active Abandoned
- 2016-04-29 TW TW105113624A patent/TW201702271A/en unknown
- 2016-05-02 UY UY0001036663A patent/UY36663A/en not_active Application Discontinuation
2017
- 2017-10-29 IL IL255314A patent/IL255314A0/en unknown
- 2017-10-30 CL CL2017002737A patent/CL2017002737A1/en unknown
- 2017-11-30 CO CONC2017/0012385A patent/CO2017012385A2/en unknown
2018
- 2018-11-20 US US16/197,066 patent/US11014979B2/en active Active
2021
- 2021-05-21 US US17/327,170 patent/US20220089705A1/en active Pending

Also Published As

Publication number	Publication date
US20220089705A1 (en)	2022-03-24
IL255314A0 (en)	2017-12-31
WO2016176656A3 (en)	2016-12-08
BR112017023158A2 (en)	2018-07-24
CA2982427A1 (en)	2016-11-03
MX2017013807A (en)	2018-03-15
UY36663A (en)	2016-07-29
EP3288584A2 (en)	2018-03-07
KR20170138570A (en)	2017-12-15
TW201702271A (en)	2017-01-16
AU2016254215A1 (en)	2017-10-26
US20160319003A1 (en)	2016-11-03
US11014979B2 (en)	2021-05-25
WO2016176656A2 (en)	2016-11-03
EA201792388A1 (en)	2018-06-29
CN107667116A (en)	2018-02-06
CO2017012385A2 (en)	2018-04-30
US20190161536A1 (en)	2019-05-30
JP2018515082A (en)	2018-06-14
US10160798B2 (en)	2018-12-25
CL2017002737A1 (en)	2018-05-25

Publication	Publication Date	Title
HUS2400014I1 (en)	2024-06-28	Therapeutic antibodies and their uses
HRP20181802T1 (en)	2018-12-28	Human cd3 binding antibody
IL262269B1 (en)	2023-04-01	Agonistic antibodies that bind human cd40 and uses thereof
IL258332A (en)	2018-05-31	Antibody agents specific for human cd19 and uses thereof
ZA201808582B (en)	2021-08-25	Antibodies to alpha-synuclein and uses thereof
GB201519858D0 (en)	2015-12-23	Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
ZA201905341B (en)	2021-10-27	Antibodies specifically binding to human il-1r7
IL255314A0 (en)	2017-12-31	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
HK1247091A1 (en)	2018-09-21	Therapeutic antibodies and uses thereof
GB201713871D0 (en)	2017-10-11	Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
IL266516B (en)	2021-12-01	Antibody binding specifically to cd66c and use thereof
SG11201704500VA (en)	2017-06-29	Antibody binding to neuropilin 1 and use thereof
HK1245811A1 (en)	2018-08-31	Antibodies that bind human c6 and uses thereof